BioMarin Pharmaceutical Inc.
BMRN
$67.48
-$0.84-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.85B | 2.75B | 2.59B | 2.47B | 2.42B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.85B | 2.75B | 2.59B | 2.47B | 2.42B |
| Cost of Revenue | 969.01M | 970.80M | 910.38M | 904.12M | 881.27M |
| Gross Profit | 1.88B | 1.78B | 1.68B | 1.57B | 1.54B |
| SG&A Expenses | 913.20M | 1.00B | 964.22M | 907.29M | 892.41M |
| Depreciation & Amortization | 43.26M | 48.84M | 59.51M | 60.84M | 62.21M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.28B | 2.41B | 2.33B | 2.27B | 2.23B |
| Operating Income | 570.04M | 340.09M | 256.72M | 201.83M | 185.77M |
| Income Before Tax | 541.76M | 391.45M | 298.68M | 237.35M | 188.56M |
| Income Tax Expenses | 114.90M | 69.16M | 42.09M | 31.90M | 20.92M |
| Earnings from Continuing Operations | 426.86 | 322.29 | 256.59 | 205.46 | 167.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 426.86M | 322.29M | 256.59M | 205.46M | 167.65M |
| EBIT | 570.04M | 340.09M | 256.72M | 201.83M | 185.77M |
| EBITDA | 666.47M | 439.77M | 363.08M | 307.15M | 290.16M |
| EPS Basic | 2.25 | 1.70 | 1.36 | 1.09 | 0.89 |
| Normalized Basic EPS | 2.06 | 1.26 | 0.95 | 0.75 | 0.67 |
| EPS Diluted | 2.20 | 1.64 | 1.30 | 1.05 | 0.86 |
| Normalized Diluted EPS | 1.98 | 1.20 | 0.91 | 0.73 | 0.65 |
| Average Basic Shares Outstanding | 760.10M | 757.89M | 755.68M | 753.51M | 751.31M |
| Average Diluted Shares Outstanding | 793.50M | 788.75M | 782.78M | 777.27M | 772.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
